METASTATIC PROSTATE CARCINOMA

This study is testing whether adding a drug called cediranib to another drug called olaparib works better than olaparib alone for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy. The trial will enroll about 90 men to see which …

This study tests whether a combination of three medications can help control advanced prostate cancer that has spread to other parts of the body. The trial involves 60 men with high-risk prostate cancer who haven't had extensive prior hormone treatment. Researchers will give part…

This study is testing whether a combination of three drugs—apalutamide, abiraterone acetate, and prednisone—can better control advanced prostate cancer that has spread to other parts of the body. The treatment is given to men who have already completed a standard chemotherapy. Th…

This study is testing whether combining two existing drugs works better than using them alone for men with advanced prostate cancer that has specific genetic flaws. It is for men whose cancer has spread and is no longer responding to standard hormone-blocking treatments. The tria…

This early-stage study is testing a new combination of two drugs, AZD8186 and docetaxel, for patients with advanced solid tumors that have specific genetic changes (PTEN or PIK3CB mutations). The main goals are to find the safest and most effective dose and to understand the side…

This is a small, early-stage safety study testing a combination of two cancer drugs, nivolumab and cabozantinib, in people living with HIV who have advanced solid tumors. The main goal is to see if the two-drug combination is safe and tolerable for this specific patient group. Re…

This early-stage study is testing a new combination of two drugs, DS3201 and ipilimumab, for people with advanced prostate, bladder, or kidney cancer that has spread. The main goals are to find the safest dose and understand the side effects. Researchers hope the drug combo will …

This study is testing a multi-step treatment to control a fast-spreading and hard-to-treat form of prostate cancer. It will involve about 120 men whose cancer has spread and is resistant to standard hormone therapy. The goal is to see if combining chemotherapy, a drug that helps …

This study is testing the safety and effectiveness of avelumab, an immunotherapy drug, when given in combination with other immune-boosting drugs and sometimes radiation. It is for patients with advanced solid tumors that have spread and who have run out of standard treatment opt…

This study is testing whether adding an experimental drug called berzosertib to a standard chemotherapy (carboplatin) works better than a different standard combination (docetaxel + carboplatin) for men with advanced prostate cancer that has spread and is no longer responding to …

This study is testing different combinations of approved drugs to find better ways to control advanced prostate cancer that has spread and stopped responding to standard hormone therapy. It involves 196 men and uses a personalized approach: after an initial 8-week treatment, pati…

This study is testing whether men with advanced prostate cancer that has spread can safely take a break from hormone-blocking medications when their cancer responds exceptionally well to treatment. The trial involves 79 men who have been on strong hormone therapy for 18-24 months…

This study is testing the safety and effectiveness of combining two drugs, enzalutamide and cabazitaxel, for men with advanced prostate cancer that has spread and is no longer responding to standard hormone treatments. The goal is to see if using these drugs together can better c…

This study aims to understand how the genetic makeup of prostate cancer changes when patients take a standard hormone therapy drug (abiraterone acetate). Researchers will collect tissue, blood, and urine samples from 92 men with advanced prostate cancer before and during treatmen…

This study investigates whether two common prostate cancer drugs (abiraterone acetate and enzalutamide) affect thinking, memory, and brain function. Researchers are following 100 men with advanced prostate cancer, using brain scans and cognitive tests to measure changes over time…